PA22-2 TFA
Based on 1 Customer Validation
PA22-2 (IKVAV sequence; Laminin A-chain fragment) TFA is a laminin receptor ligand. PA22-2 TFA competes with laminin for receptor binding sites, thereby mediating biological responses such as cell adhesion, migration, morphology regulation and angiogenesis. PA22-2 TFA promotes adhesion, spreading, directional migration and axon growth of specific cells, and supports endothelial cell mobilization and vascular formation. PA22-2 TFA inhibits laminin-mediated adhesion and migration in melanoma cells, and its antiserum reacts with the laminin A chain and native laminin, effectively blocking cell adhesion and axon growth.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté: 95.77%
- Formule: C82H150N32O25S·xC2HF3O2
- Masse moléculaire:2016.33 (free base)
-
Stockage:
Sealed storage, away from moisture.
Powder -80°C, 2 years , -20°C, 1 year* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Activité biologique
PA22-2 TFA (200 μg; 2 h coverslip coating, 18 h cell incubation) induces a fibroblastoid, migratory morphology in human umbilical vein endothelial cells (HUVEC), with most cells losing contact inhibition and developing extended cellular processes[2].
PA22-2 TFA (200 μg/mL; 6 h) induces a threefold increase in type IV collagenase activity, including active forms at 68 Kd and 62 Kd, in human umbilical vein endothelial cells (HUVEC) on Matrigel, leading to degradation of the Matrigel matrix and release of collagen IV fragments[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
PA22-2 TFA (200 μg; topical application via coated coverslip) significantly stimulates angiogenesis in the chick chorioallantoic membrane assay, increasing mean vessel area relative to untreated controls[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Fertilized eggs, 4-day-old[2]
-
Dosage:2 mg/mL
-
Administration:topical application to yolk sac membrane
-
Result:Stimulated angiogenesis, increasing vessel thickness, abundance, and branching in 27 out of 30 eggs tested.
-
Animal Model:Fertilized eggs, 9-day-old[2]
-
Dosage:200 μg
-
Administration:topical application via coated coverslip
-
Result:Increased the mean vessel area to 4.2, with a statistically significant P-value of 0.019 compared to no treatment.
Chemical Information
-
Appearance Solid
-
Masse moléculaire 2016.33 (free base)
-
Formule C82H150N32O25S·xC2HF3O2
-
SMILES
O=C(N[C@@H](CO)C(N[C@@H](CCCNC(N)=N)C(N[C@@H](C)C(N[C@@H](CCCNC(N)=N)C(N[C@@H](CCCCN)C(N[C@@H](CCC(N)=O)C(N[C@@H](C)C(N[C@@H](C)C(N[C@@H](CO)C(N[C@@H]([C@@H](C)CC)C(N[C@@H](CCCCN)C(N[C@@H](C(C)C)C(N[C@@H](C)C(N[C@@H](C(C)C)C(N[C@@H](CO)C(N[C@@H](C)C(N[C@@H](CC(O)=O)C(N[C@@H](CCCNC(N)=N)C(N)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)[C@H](CS)N.OC(C(F)(F)F)=O.[x]
-
Synonyms
IKVAV sequence TFA; Laminin A-chain fragment TFA
-
Sequence
Cys-Ser-Arg-Ala-Arg-Lys-Gln-Ala-Ala-Ser-Ile-Lys-Val-Ala-Val-Ser-Ala-Asp-Arg-NH2
-
Sequence Shortening
CSRARKQAASIKVAVSADR-NH2
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Sealed storage, away from moisture
Powder -80°C 2 years -20°C 1 year * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Solvant et solubilité
H2O : 50 mg/mL (Need ultrasonic)
Pureté et documentation
Références
[1]. Tashiro K, et al. A synthetic peptide containing the IKVAV sequence from the A chain of laminin mediates cell attachment, migration, and neurite outgrowth. The Journal of biological chemistry. 1989 Sep 25;264(27):16174-82. [Content Brief]
[2]. Grant DS, et al. Interaction of endothelial cells with a laminin A chain peptide (SIKVAV) in vitro and induction of angiogenic behavior in vivo. Journal of cellular physiology. 1992 Dec;153(3):614-25. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)